An Analysis Regarding the Association Between Proteasome (PSM) and Hepatocellular Carcinoma (HCC)
Journal of Hepatocellular Carcinoma · 2023-03 · Volume 10 · 497-515
DOI: 10.2147/jhc.s404396 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2023-03. Verfasst von Wei Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangs…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
The Proteasome (PSM) is a large multi-catalytic protease complex consisting of a 20S core particle and a 19S regulatory particle whose main function is to accept and degrade ubiquitinated substrates, are now considered as one of the potential regulators of tumor proliferation, and stemness maintenance. However, to date, studies on the relationship between PSM and hepatocellular carcinoma (HCC) are limited.
Methods
This study used a bioinformatics approach combining validation experiments to investigate the biological mechanisms that may be related with PSM. A series of experiments in vivo and in vitro were performed to explore the function of the 26S proteasome non-ATPase regulatory subunit 13 (PSMD13) in HCC.
Results
HCC patients can be divided into two clusters. Cluster 1 (C1) patients having a significantly worse prognosis than Cluster (C2). Two subtypes had significant differences in proliferation-related signaling. In particular, the frequency of TP53 mutation was significantly higher in C1 than in C2. In addition, PSM-associated genes were highly consistent with the expression of DNA repair-related signatures, suggesting a potential link between PSM and genomic instability. We also found that downregulation of PSMD13 expression significantly inhibited stemness of tumor cells and impaired the Epithelial mesenchymal transition (EMT) process. Finally, the correlation between the PSMD13 and Ki67 was found to be strong.
Conclusion
PSM is a valid predictor of prognosis and therapeutic response in patients with HCC disease. Furthermore, PSMD13 may be a potential therapeutic target.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu, 210029, People's Republic of China.
- Comprehensive Cancer Center, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210008, People's Republic of China.
- Department of Pathology, Nanjing Jinling Hospital, Nanjing, Jiangsu, 210001, People's Republic of China.
- No. 1 Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, People's Republic of China.
- Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu, 215600, People's Republic of China.
- Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing, 210023, People's Republic of China.
ORCID-Profile: Yuan-Jie Liu, Xiao-Ping Qian
Zitieren
APA
Huang, W., Mei, J., Liu, Y. J., Li, J. P., Zou, X., Qian, X. P., & Zhang, Y. (2023). An Analysis Regarding the Association Between Proteasome (PSM) and Hepatocellular Carcinoma (HCC). Journal of Hepatocellular Carcinoma, Volume 10, 497-515. https://doi.org/10.2147/jhc.s404396
Vancouver
Huang W, Mei J, Liu YJ, Li JP, Zou X, Qian XP, et al. An Analysis Regarding the Association Between Proteasome (PSM) and Hepatocellular Carcinoma (HCC). Journal of Hepatocellular Carcinoma. 2023;Volume 10:497-515. doi:10.2147/jhc.s404396
BibTeX
@article{Huang2023,
author = {Huang, Wei and Mei, Jia and Liu, Yuan-Jie and Li, Jie-Pin and Zou, Xi and Qian, Xiao-Ping and Zhang, Yu},
title = {An Analysis Regarding the Association Between Proteasome (PSM) and Hepatocellular Carcinoma (HCC)},
journal = {Journal of Hepatocellular Carcinoma},
year = {2023},
volume = {Volume 10},
pages = {497--515},
doi = {10.2147/jhc.s404396}
}
EUVIMED